An imaging industry advocate is blasting the federal government’s recent decision to continue severely restricting access to treatments for Alzheimer’s.

CMS announced in February that it will not reconsider the agency’s national coverage determination on monoclonal antibodies directed against amyloid for the treatment of this deadly disease. The move drew anger from the Alzheimer's Association, which had originally requested the reexamination.

Now, the Medical Imaging & Technology Alliance also is weighing in, urging the federal government to “immediately” revisit the decision.